EN
Instrument Fundamentals
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
News
Vir Biotechnology (NASDAQ:VIR) Reaches New 1-Year Low - Here's Why
Vir Biotechnology, Inc. (NASDAQ:VIR) is favoured by institutional owners who hold 53% of the company
Fox Run Management L.L.C. Takes $364,000 Position in Vir Biotechnology, Inc. (NASDAQ:VIR)
49,651 Shares in Vir Biotechnology, Inc. (NASDAQ:VIR) Acquired by Fox Run Management L.L.C.
Vir Biotechnology, Inc. (NASDAQ:VIR) Holdings Raised by Charles Schwab Investment Management Inc.
Bank of New York Mellon Corp Lowers Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)
Vir Biotechnology enrolls first patient in ECLIPSE program | Markets Insider
Vir Biotechnology, Inc. (NASDAQ:VIR) Receives $35.67 Consensus Target Price from Analysts
Hepatitis B Virus Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies | ABNewswire
Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Purchased by New York State Common Retirement Fund
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Recommendation of "Moderate Buy" by Analysts
Vir Biotechnology (NASDAQ:VIR) Shares Gap Down - Time to Sell?
489,485 Shares in Vir Biotechnology, Inc. (NASDAQ:VIR) Acquired by Alta Partners Management Company L.P.
Vir Biotechnology (NASDAQ:VIR) Price Target Raised to $31.00 at Barclays
Analysts Have Lowered Expectations For Vir Biotechnology, Inc. (NASDAQ:VIR) After Its Latest Results
Vir Biotechnology (NASDAQ:VIR) Trading Down 8.4% on Insider Selling
Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Sells $67,389.22 in Stock
Vir Biotechnology (NASDAQ:VIR) Earns Buy Rating from Needham & Company LLC
Needham & Company LLC Reaffirms Buy Rating for Vir Biotechnology (NASDAQ:VIR)
Vir Biotechnology price target raised to $31 from $26 at Barclays | Markets Insider
Barclays Remains a Buy on Vir Biotechnology (VIR) | Markets Insider
Decoding Vir Biotechnology Inc (VIR): A Strategic SWOT Insight
